Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro - PubMed
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al. Cell Res. 2020 Mar.
No abstract available
Conflict of interest statement
The authors declare no competing interests.
Figures

a Vero E6 cells were infected with 2019-nCoV at an MOI of 0.05 in the treatment of different doses of the indicated antivirals for 48 h. The viral yield in the cell supernatant was then quantified by qRT-PCR. Cytotoxicity of these drugs to Vero E6 cells was measured by CCK-8 assays. The left and right Y-axis of the graphs represent mean % inhibition of virus yield and cytotoxicity of the drugs, respectively. The experiments were done in triplicates. b Immunofluorescence microscopy of virus infection upon treatment of remdesivir and chloroquine. Virus infection and drug treatment were performed as mentioned above. At 48 h p.i., the infected cells were fixed, and then probed with rabbit sera against the NP of a bat SARS-related CoV as the primary antibody and Alexa 488-labeled goat anti-rabbit IgG (1:500; Abcam) as the secondary antibody, respectively. The nuclei were stained with Hoechst dye. Bars, 100 μm. c and d Time-of-addition experiment of remdesivir and chloroquine. For “Full-time” treatment, Vero E6 cells were pre-treated with the drugs for 1 h, and virus was then added to allow attachment for 2 h. Afterwards, the virus–drug mixture was removed, and the cells were cultured with drug-containing medium until the end of the experiment. For “Entry” treatment, the drugs were added to the cells for 1 h before viral attachment, and at 2 h p.i., the virus–drug mixture was replaced with fresh culture medium and maintained till the end of the experiment. For “Post-entry” experiment, drugs were added at 2 h p.i., and maintained until the end of the experiment. For all the experimental groups, cells were infected with 2019-nCoV at an MOI of 0.05, and virus yield in the infected cell supernatants was quantified by qRT-PCR c and NP expression in infected cells was analyzed by Western blot d at 14 h p.i.
Comment in
-
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Colson P, et al. Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4. Int J Antimicrob Agents. 2020. PMID: 32145363 Free PMC article. No abstract available.
-
Spinelli FR, Ceccarelli F, Di Franco M, Conti F. Spinelli FR, et al. Ann Rheum Dis. 2020 May;79(5):666-667. doi: 10.1136/annrheumdis-2020-217367. Epub 2020 Apr 2. Ann Rheum Dis. 2020. PMID: 32241791 No abstract available.
-
Chloroquine hype is derailing the search for coronavirus treatments.
Ledford H. Ledford H. Nature. 2020 Apr;580(7805):573. doi: 10.1038/d41586-020-01165-3. Nature. 2020. PMID: 32332911 No abstract available.
-
Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety.
Jeevaratnam K. Jeevaratnam K. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):256-257. doi: 10.1093/ehjcvp/pvaa041. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 32347923 Free PMC article. No abstract available.
Similar articles
-
Rapid review for the anti-coronavirus effect of remdesivir.
Li Z, Wang X, Cao D, Sun R, Li C, Li G. Li Z, et al. Drug Discov Ther. 2020;14(2):73-76. doi: 10.5582/ddt.2020.01015. Drug Discov Ther. 2020. PMID: 32378648 Review.
-
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Li G, De Clercq E. Li G, et al. Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0. Nat Rev Drug Discov. 2020. PMID: 32127666 No abstract available.
-
Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Malin JJ, et al. Clin Microbiol Rev. 2020 Oct 14;34(1):e00162-20. doi: 10.1128/CMR.00162-20. Print 2020 Dec 16. Clin Microbiol Rev. 2020. PMID: 33055231 Free PMC article. Review.
-
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA. Martinez MA. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00399-20. doi: 10.1128/AAC.00399-20. Print 2020 Apr 21. Antimicrob Agents Chemother. 2020. PMID: 32152082 Free PMC article. Review.
-
Uzunova K, Filipova E, Pavlova V, Vekov T. Uzunova K, et al. Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24. Biomed Pharmacother. 2020. PMID: 32861965 Free PMC article. Review.
Cited by
-
Current COVID-19 treatments: Rapid review of the literature.
Dong Y, Shamsuddin A, Campbell H, Theodoratou E. Dong Y, et al. J Glob Health. 2021 Apr 24;11:10003. doi: 10.7189/jogh.11.10003. J Glob Health. 2021. PMID: 33959261 Free PMC article. Review.
-
Kumari M, Kumar A. Kumari M, et al. Sci Total Environ. 2021 Jul 15;778:146303. doi: 10.1016/j.scitotenv.2021.146303. Epub 2021 Mar 9. Sci Total Environ. 2021. PMID: 34030377 Free PMC article.
-
Tomita Y, Takeda M, Matsuyama S. Tomita Y, et al. Antimicrob Agents Chemother. 2023 May 1;65(5):e00020-21. doi: 10.1128/AAC.00020-21. Epub 2021 Mar 1. Antimicrob Agents Chemother. 2023. PMID: 33649117 Free PMC article.
-
Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.
Sheervalilou R, Shirvaliloo M, Sargazi S, Bahari S, Saravani R, Shahraki J, Shirvalilou S, Shahraki O, Nazarlou Z, Shams Z, Ghaznavi H. Sheervalilou R, et al. Blood Purif. 2022;51(1):1-14. doi: 10.1159/000513164. Epub 2021 Mar 31. Blood Purif. 2022. PMID: 33789273 Free PMC article. Review.
-
Iacobazzi D, Baquedano M, Madeddu P, Caputo M. Iacobazzi D, et al. Front Cardiovasc Med. 2020 Jul 14;7:140. doi: 10.3389/fcvm.2020.00140. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 32760740 Free PMC article. Review.
References
-
- Huang Chaolin, Wang Yeming, Li Xingwang, Ren Lili, Zhao Jianping, Hu Yi, Zhang Li, Fan Guohui, Xu Jiuyang, Gu Xiaoying, Cheng Zhenshun, Yu Ting, Xia Jiaan, Wei Yuan, Wu Wenjuan, Xie Xuelei, Yin Wen, Li Hui, Liu Min, Xiao Yan, Gao Hong, Guo Li, Xie Jungang, Wang Guangfa, Jiang Rongmeng, Gao Zhancheng, Jin Qi, Wang Jianwei, Cao Bin. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
-
- Zhou, P. et al. Nature (accepted).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials